Comparative Pharmacology
Head-to-head clinical analysis: MUPIROCIN versus XERAVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MUPIROCIN versus XERAVA.
MUPIROCIN vs XERAVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase, inhibiting protein synthesis.
Eravacycline is a tetracycline-class antibacterial that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A-site. It exhibits activity against a broad range of Gram-positive, Gram-negative, and anaerobic bacteria, including many tetracycline-resistant strains due to modifications circumventing common resistance mechanisms.
Apply a small amount of 2% ointment or cream to affected area three times daily for 5 to 14 days.
200 mg intravenously over 60 minutes every 12 hours
None Documented
None Documented
Clinical Note
moderateMupirocin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mupirocin."
Intravenous: ~30 min (0.5 h). Topical: systemically absorbed amount negligible, local half-life not defined.
Terminal elimination half-life is approximately 42 hours (range 30-60 hours) in healthy subjects; prolonged in elderly patients and those with severe hepatic impairment.
Renal: <1% unchanged (topical); hepatic metabolism to monic acid, eliminated renally and fecally. After IV administration, 60-70% renal, 20-30% fecal/biliary.
Fecal (approximately 80-90% as unchanged drug); renal (less than 1% as unchanged drug).
Category A/B
Category C
Antibiotic
Antibiotic